BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18830256)

  • 1. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations.
    Dvorakova D; Lengerova M; Pospisilova J; Palasek I; Mayer J
    Leukemia; 2009 Apr; 23(4):793-6. PubMed ID: 18830256
    [No Abstract]   [Full Text] [Related]  

  • 2. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of the nucleophosmin gene mutations in acute myelogenous leukemia through RT-PCR and polyacrylamide gel electrophoresis.
    Calvo KL; Ojeda MJ; Ammatuna E; Lavorgna S; Ottone T; Targovnik HM; Lo-Coco F; Noguera NI
    Eur J Haematol; 2009 Jan; 82(1):69-72. PubMed ID: 18801061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
    Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
    Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.
    Gorello P; Cazzaniga G; Alberti F; Dell'Oro MG; Gottardi E; Specchia G; Roti G; Rosati R; Martelli MF; Diverio D; Lo Coco F; Biondi A; Saglio G; Mecucci C; Falini B
    Leukemia; 2006 Jun; 20(6):1103-8. PubMed ID: 16541144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia.
    Scholl S; Mügge LO; Landt O; Loncarevic IF; Kunert C; Clement JH; Höffken K
    Leuk Res; 2007 Sep; 31(9):1205-11. PubMed ID: 17306368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations.
    Chou WC; Tang JL; Wu SJ; Tsay W; Yao M; Huang SY; Huang KC; Chen CY; Huang CF; Tien HF
    Leukemia; 2007 May; 21(5):998-1004. PubMed ID: 17361227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NPM1 for MRD? Droplet Like It's Hot!
    Wertheim GBW; Bagg A
    J Mol Diagn; 2017 Jul; 19(4):498-501. PubMed ID: 28645444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
    Krönke J; Schlenk RF; Jensen KO; Tschürtz F; Corbacioglu A; Gaidzik VI; Paschka P; Onken S; Eiwen K; Habdank M; Späth D; Lübbert M; Wattad M; Kindler T; Salih HR; Held G; Nachbaur D; von Lilienfeld-Toal M; Germing U; Haase D; Mergenthaler HG; Krauter J; Ganser A; Göhring G; Schlegelberger B; Döhner H; Döhner K
    J Clin Oncol; 2011 Jul; 29(19):2709-16. PubMed ID: 21555683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor.
    Papadaki C; Dufour A; Seibl M; Schneider S; Bohlander SK; Zellmeier E; Mellert G; Hiddemann W; Spiekermann K
    Br J Haematol; 2009 Feb; 144(4):517-23. PubMed ID: 19055671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
    Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
    Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
    Mencia-Trinchant N; Hu Y; Alas MA; Ali F; Wouters BJ; Lee S; Ritchie EK; Desai P; Guzman ML; Roboz GJ; Hassane DC
    J Mol Diagn; 2017 Jul; 19(4):537-548. PubMed ID: 28525762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype.
    Zhang Y; Zhang M; Yang L; Xiao Z
    Leuk Res; 2007 Jan; 31(1):109-11. PubMed ID: 16678898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
    Salipante SJ; Fromm JR; Shendure J; Wood BL; Wu D
    Mod Pathol; 2014 Nov; 27(11):1438-46. PubMed ID: 24743218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
    Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
    Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of methods for detection of NPM1 gene mutations in acute myeloid leukemia].
    Li ZP; Zhang X; Zhao XM; Li QG; Chen YM; Lu QY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):999-1004. PubMed ID: 21867632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene.
    Jeziskova I; Razga F; Toskova M; Dvorakova D; Timilsina S; Mayer J; Racil Z
    Leuk Lymphoma; 2013 Apr; 54(4):867-70. PubMed ID: 22950897
    [No Abstract]   [Full Text] [Related]  

  • 18. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
    Sorigue M; Espasa A; Zamora L; Junca J
    Ann Hematol; 2020 May; 99(5):1135-1136. PubMed ID: 32170360
    [No Abstract]   [Full Text] [Related]  

  • 19. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
    Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
    Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
    Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
    Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.